RxDoctor Payments Data

Deven Patel, MD

Cardiovascular Disease · Ocoee, FLNPI 1215198833

Payments from drug & device makers

$5,633in general payments, 2019–2025

Across 31 payments — averaging $181.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$4K
  • Abbott$897
  • Bolton Medical Inc$316
  • Atricure, Inc.$238
  • Pfizer$118
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$103
  • plus $182 from 4 others
$108in research payments, 2019–2025

Across 1 payment — averaging $108.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abiomed$108

What the payments were for

  • Food & beverage$67012%
  • Education$4,96388%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,633 in reported general payments places this provider in the 60th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$226,640
Medicare patients
691
Services billed
2,783

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban378$441,284
EntrestoSacubitril/Valsartan135$181,959
Repatha SureclickEvolocumab102$96,221
VascepaIcosapent Ethyl121$90,372
XareltoRivaroxaban79$77,261
JardianceEmpagliflozin23$27,386
FarxigaDapagliflozin Propanediol22$23,910
Icosapent Ethyl27$12,478
Ranolazine ErRanolazine56$6,474
Metoprolol Succinate500$6,440
Rosuvastatin Calcium392$5,366
Praluent PenAlirocumab11$5,240
Atorvastatin Calcium419$3,471
Ezetimibe174$2,618
Nitroglycerin234$2,154

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$118$441,284378 claims
NovartisEntresto$57$181,959135 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Ocoee

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →